Patents by Inventor Charles William Blackledge, JR.

Charles William Blackledge, JR. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Enhancer of zeste homolog 2 inhibitors
    Patent number: 9790212
    Abstract: This invention relates to novel compounds according to Formula (III)(a) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), and to pharmaceutical compositions containing them.
    Type: Grant
    Filed: October 13, 2016
    Date of Patent: October 17, 2017
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED
    Inventors: Charles William Blackledge, Jr., Joelle Lorraine Burgess, Neil W. Johnson, Jiri Kasparec, Steven David Knight, Louis V. LaFrance, III, Juan I. Luengo, William Henry Miller, Kenneth Allen Newlander, Stuart Paul Romeril, Mark Schulz, Dai-Shi Su, Xinrong Tian
  • ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS
    Publication number: 20170029412
    Abstract: This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.
    Type: Application
    Filed: October 13, 2016
    Publication date: February 2, 2017
    Inventors: Charles William BLACKLEDGE, JR., Joelle Lorraine BURGESS, Neil W. JOHNSON, Jiri KASPAREC, Steven David KNIGHT, Louis V. LaFRANCE, III, Juan I. LUENGO, William Henry MILLER, Kenneth Allen NEWLANDER, Stuart Paul ROMERIL, Mark SCHULZ, Dai-Shi SU, Xinrong TIAN
  • Enhancer of zeste homolog 2 inhibitors
    Patent number: 9505745
    Abstract: This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.
    Type: Grant
    Filed: April 25, 2014
    Date of Patent: November 29, 2016
    Assignee: GlaxoSmithKline Intellectual Property (No. 2) Limited
    Inventors: Charles William Blackledge, Jr., Joelle Lorraine Burgess, Neil W. Johnson, Jiri Kasparec, Steven David Knight, Louis V. LaFrance, III, Juan I. Luengo, William Henry Miller, Kenneth Allen Newlander, Stuart Paul Romeril, Mark Schulz, Dai-Shi Su, Xinrong Tian
  • ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS
    Publication number: 20160102083
    Abstract: This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.
    Type: Application
    Filed: April 25, 2014
    Publication date: April 14, 2016
    Applicant: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
    Inventors: Charles William BLACKLEDGE, JR., Joelle Lorraine BURGESS, Neil W. JOHNSON, Jiri KASPAREC, Steven David KNIGHT, Louis V. LaFRANCE, III, Juan I. LUENGO, William Henry MILLER, Kenneth Allen NEWLANDER, Stuart Paul ROMERIL, Mark SCHULZ, Dai-Shi SU, Xinrong TIAN
  • Chemical compounds
    Patent number: 8697685
    Abstract: The invention is directed to 6-(4-pyrimidinyl)-1H-indazole derivatives. Specifically, the invention is directed to compounds according to Formula (I) wherein R1-R4 are defined herein. The compounds of the invention axe inhibitors of PDK1 and can be useful in the treatment of immune and metabolic diseases and disorders characterized by constitutively activated ACG kinases such as cancer and more specifically cancers of the breast, colon, and lung. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PDK1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
    Type: Grant
    Filed: November 18, 2009
    Date of Patent: April 15, 2014
    Assignee: GlaxoSmithKline LLC
    Inventors: Jeffrey Michael Axten, Charles William Blackledge, Jr., Gerald Patrick Brady, Jr., Yanhong Feng, Seth W. Grant, Jesus Raul Medina, William H. Miller, Stuart P. Romeril
  • CHEMICAL COMPOUNDS
    Publication number: 20110275611
    Abstract: The invention is directed to 6-(4-pyrimidinyl)-1H-indazole derivatives. Specifically, the invention is directed to compounds according to Formula (I) wherein R1-R4 are defined herein. The compounds of the invention axe inhibitors of PDK1 and can be useful in the treatment of immune and metabolic diseases and disorders characterized by constitutively activated ACG kinases such as cancer and more specifically cancers of the breast, colon, and lung. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention.
    Type: Application
    Filed: November 18, 2009
    Publication date: November 10, 2011
    Inventors: Jeffrey Michael Axten, Charles William Blackledge, JR., Gerald Patrick Brady, JR., Yanhong Feng, Seth W. Grant, Jesus Raul Medina, William H. Miller, Stuart P. Romeril